For the millions of adults living with autoimmune rheumatic diseases, the calculus around vaccination is far more complex than for the general population — and the stakes are considerably higher. This population faces compounding vulnerability: disease-driven immune dysregulation, chronic immunosuppression, age-related immunosenescence, and comorbidities that collectively amplify susceptibility to vaccine-preventable infections. Understanding how to optimize protection within these constraints has become an urgent clinical priority.
The review synthesizes evidence across multiple vaccine-preventable illnesses and treatment contexts, identifying a hierarchy of immunological risk. Conventional immunosuppressants present one tier of challenge, but next-generation biologics — particularly B cell-depleting agents such as rituximab, chimeric antigen receptor T cell (CAR-T) therapies, and bispecific T cell engagers — pose a qualitatively different problem: they can severely blunt both humoral and cellular immune responses to vaccination, effectively rendering standard immunization schedules unreliable. Timing vaccination relative to these therapies emerges as a central strategic variable. The analysis also flags persistently suboptimal uptake of routinely recommended vaccines, including influenza and pneumococcal immunizations, driven substantially by patient concerns about disease flares and the theoretical induction of new autoimmune phenomena — concerns that evidence does not broadly support.
This review lands at a genuinely important inflection point. The rapid expansion of advanced biologics in rheumatology has outpaced the evidence base for vaccination protocols in patients receiving them. Most existing studies measure surrogate endpoints — antibody titers and T cell responses — rather than real-world clinical effectiveness or long-term immunity durability, leaving clinicians without robust guidance on booster intervals or threshold responses. The COVID-19 pandemic functioned as an unplanned stress test, exposing gaps in both adherence and protection among this cohort. The review's scope is broad rather than mechanistically novel, positioning it as a clinically valuable synthesis rather than a paradigm-shifting primary finding. Its most actionable contribution is the emphasis on treatment-synchronized vaccination timing as a modifiable lever — one that remains underutilized despite its logical and emerging empirical basis.